TipRanks
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
US Market
DNTH
Dianthus Therapeutics
RESEARCH TOOLSreports
Want to see DNTH full AI Analyst Report?

Dianthus Therapeutics (DNTH) Stock News & Sentiment

441 Followers
Dianthus Reaffirmed at Buy as Claseprubart Data Strengthen Neuromuscular Outlook; Price Target Maintained at $125
Premium
Ratings
Dianthus Reaffirmed at Buy as Claseprubart Data Strengthen Neuromuscular Outlook; Price Target Maintained at $125
1d ago
DNTH
Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile
Premium
Ratings
Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile
13d ago
DNTH
Dianthus Maintained at Buy as Strong Cash Runway and DNTH312 Pipeline Potential Support Unchanged $125 Price Target
Premium
Ratings
Dianthus Maintained at Buy as Strong Cash Runway and DNTH312 Pipeline Potential Support Unchanged $125 Price Target
2M ago
DNTH
Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market
Premium
Company Announcements
Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market
3M ago
DNTH
Dianthus Highlights Positive CAPTIVATE Phase 3 Interim Results
Premium
Company Announcements
Dianthus Highlights Positive CAPTIVATE Phase 3 Interim Results
4M ago
8K
DNTH
Analyst Maintains Buy Rating on Claseprubart Developer, Keeps $125 Price Target Unchanged Amid Confidence in Trial Design and Potency
Premium
Ratings
Analyst Maintains Buy Rating on Claseprubart Developer, Keeps $125 Price Target Unchanged Amid Confidence in Trial Design and Potency
4M ago
DNTH
Analyst Reiterates Buy on Dianthus Therapeutics, Keeping $130 Price Target Amid Confidence in Claseprubart’s Best-in-Class Potential
Premium
Ratings
Analyst Reiterates Buy on Dianthus Therapeutics, Keeping $130 Price Target Amid Confidence in Claseprubart’s Best-in-Class Potential
4M ago
DNTH
More DNTH News >

DNTH News on the Web

Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile
TipRanks News
Bullish
Fairmount Funds Management LLC Acquires New Stake in Cyclerion Therapeutics Inc (CYCN)
GuruFocus News
Neutral
Fairmount Funds Management LLC Exits Apogee Therapeutics Inc (APGE) Position Entirely
GuruFocus News
Neutral
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
Insider Monkey
Neutral
Why Dianthus Therapeutics’ Hot Rally Is Suddenly Fading
TipRanks News
Neutral
New Autoimmune Drug Sends Dianthus Therapeutics Soaring
TipRanks News
Bullish
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Elanco Animal Health (ELAN)
TipRanks News
Bullish
Top Executive Makes Bold Move With Major Dianthus Therapeutics Stock Sale
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
DNTH
Sector Average
Media Buzz
This Week1 articles
Weekly Average4.5 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DNTH’s Media Buzz Sentiment?
1 articles about DNTH were published this week. In an average week, 4.5 articles are published.
    What is DNTH’s weekly average amount of articles?
    In an average week, 4.5 articles about DNTH are published.
      What is DNTH’s News Sentiment?
      100% of articles about DNTH were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        SMMTSummit Therapeutics
        CDNACareDx
        ARGXArgenx Se
        MEOBFMesoblast Limited
        KODKodiak Sciences
        Showing the stocks with the most bullish news sentiment over the past week